← Back to patent-cliff list
Pozdeutinurad
Tier C — Watch / tradePozdeutinurad
Arthrosi Therapeutics Inc
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：URAT1
Indications (approved)：Hyperuricaemia, Gout, 痛风性关节炎, Renal impairment
Regional status
US
Phase III
2024-06-26
EU
-
China
Phase III
2024-04-22
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Pozdeutinurad?
Approved indications include: Hyperuricaemia, Gout, 痛风性关节炎, Renal impairment.
When does the Pozdeutinurad patent expire?
No public expiry year is available for Pozdeutinurad yet; this page updates once verified.
How do I get a quote for Pozdeutinurad intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-01